Unlocking Alzheimer's: Can Genetics & Brain Scans Predict Your Risk?
"New research explores how TOMM40 gene variants and brain imaging could help identify Alzheimer's risk in healthy adults."
Alzheimer's disease (AD) is a complex condition influenced by both genetic and environmental factors. While genes like APOE are known to play a role, they don't fully explain who will develop AD. Researchers are constantly searching for new ways to identify people at risk, even before symptoms start.
One promising area of research involves the TOMM40 gene, which is linked to APOE and may affect how brain cells function. Scientists are also using brain imaging techniques, like FDDNP-PET scans, to visualize the buildup of plaques and tangles in the brain – hallmarks of Alzheimer's.
A new study explores whether specific variations in the TOMM40 gene, combined with brain imaging results, can help predict Alzheimer's risk in healthy older adults. This article breaks down the study's findings and explains what they could mean for the future of Alzheimer's prevention and treatment.
Expanding Genetic Map of Alzheimer’s
Alzheimer’s disease has a strong genetic predisposition, and genome-wide association studies have identified multiple risk loci, although many non-coding variants remain uncharacterized. The National Institute on Aging reports that researchers’ knowledge has grown from 10 genes linked to Alzheimer’s a decade ago to more than 70 relevant genetic regions, with NIH funding contributing substantially to these findings. Genetic variations are one of several possible risk or protective factors, rather than the only influence on disease risk.
Inherited Risk and Late-Onset Disease
Alzheimer’s is a progressive neurological disorder that gradually impairs memory, thinking, and behavior, and is the most common cause of dementia, according to Biology Insights. Science Insights describes most Alzheimer’s cases as late-onset, developing after age 65 and influenced by genetic risk factors rather than deterministic mutations. It also reports that some genetic errors may prime the brain for pathology decades before clinical symptoms appear.
Decoding TOMM40: How Gene Length Impacts Alzheimer's Risk
The TOMM40 gene provides instructions for making a protein that helps transport other proteins into mitochondria. Mitochondria are the powerhouses of our cells. The length of a specific section within the TOMM40 gene, called the 'poly-T' region, varies from person to person. Prior research has suggested the length of this poly-T region could be associated with a person's risk of developing Alzheimer's.
- The study used FDDNP-PET scans to measure the levels of plaque and tangle deposits in the medial temporal lobe (MTL), a brain region affected early in Alzheimer's disease.
- Researchers then analyzed how TOMM40 and APOE4 gene variants correlated with plaque and tangle buildup in the MTL, as well as with cognitive performance on memory, language, attention, and executive function tests.
TOMM40, APOE, and Brain Imaging Findings
Research cited in the supplied studies links TOMM40 variation and TOMM40’523-APOE haplotypes with Alzheimer’s-related neuroimaging findings. One PET study reported greater medial temporal lobe amyloid and tau binding in S/VL individuals, which the authors said may point to a preclinical change. Other cited work reports associations between longer TOMM40 poly-T lengths and higher medial temporal plaque and neurofibrillary-tangle burden in non-demented older adults. A separate report notes that TOMM40’523 affects APOE and TOMM40 mRNA expression in temporal and occipital cortices.
Imaging Associations Did Not Track Cognitive Scores
In the reported study, researchers found no significant relationship between TOMM40 poly-T lengths or APOE risk groups and cognitive scores in any assessed domain. The multivariate result was F(12,140) = 0.7, p = .7, and the univariate p-values ranged from .5 to .9. This finding limits what those genetic groupings could show about cognitive performance in that study, even though the study title describes associations with medial temporal tau and amyloid binding on FDDNP-PET.
Risk Genes Versus Disease-Causing Variants
Alzheimer’s genetic risk spans more than one kind of genetic finding: the supplied comparison article distinguishes risk genes from inherited disease-causing variants and notes that testing has limits. Separately, a 2025 review describes Alzheimer disease as currently established by amyloid-β and tau protein biomarkers in the setting of clinical cognitive impairment. The review emphasizes that these diagnostic parameters coexist with substantial complexity in the genetic architecture underlying risk and presentation.
What Does This Mean for You? The Future of Alzheimer's Prediction
This research offers a glimpse into the potential for using genetic information and brain imaging to identify individuals at increased risk of Alzheimer's disease, even before they experience any noticeable symptoms. This could be important because treatments are most effective when started early.
Risk Loci and the Complexity of Genetic Risk
A 2026 updated genome-wide association study meta-analysis identified 91 Alzheimer’s disease and related-dementia risk loci among individuals of European ancestry; the supplied snippet says 56 loci were also identified in a further result but does not specify what that number represents. A 2025 multi-ancestry study describes age, APOE genotype, and sex as explaining much of Alzheimer’s risk, while investigating genetic modifiers of age at onset. A review underscores that Alzheimer’s is established using amyloid-β and tau biomarkers alongside clinical cognitive impairment, despite the complexity of its genetic architecture.
A Holistic Approach to Alzheimer’s
A comprehensive review argues that addressing Alzheimer’s disease requires integrating clinical, genetic, and environmental factors. It presents this holistic approach as essential to tackling the disease’s multifaceted challenges and improving outcomes for patients and caregivers. A separate review focuses on genetic risk factors for late-onset Alzheimer’s and their role in disease pathogenesis, placing genetic research within that broader effort.
The study highlights the complex interplay of genes in Alzheimer's and also reinforces that AD is a highly heterogeneous disorder, and neither genetic nor imaging markers alone are likely to be useful in definitively predicting who will develop AD. The current finding that FDDNP binding is related to a genetic risk factor for AD may imply that there are changes in the brain that may be phenotypic in prodromal AD.
While more research is needed, these findings suggest that we may one day be able to develop personalized risk assessments based on an individual's genetic makeup, brain imaging results, and lifestyle factors. This could lead to earlier interventions, more targeted treatments, and ultimately, a better chance of preventing or delaying the onset of Alzheimer's disease.